Visuel du virus de la variole du singe - Monkeypox

Monkeypox Cases: Update as of August 29, 2022

Update as of August 29, 2022, following reports of monkeypox cases in France and around the world. The next update will be released on September 1.

This report was compiled using data as of Monday at noon rather than the usual Tuesday at noon. This change in the reporting date may have contributed to the lower number of new cases observed since the last report was issued.

In early May 2022, cases of monkeypox with no direct link to travel to Central or West Africa—where the virus is present—or to people returning from travel were reported in Europe and around the world. Since then, the disease has been subject to enhanced surveillance in France and across Europe. To date, 3,547 biologically confirmed cases have been recorded in France.

Update on the Situation in France

As of August 29, 2022, at 12:00 p.m., 3,547 biologically confirmed cases had been recorded in France.

The distribution of confirmed cases by region of residence (or by region of reporting when the region of residence is unknown) is shown in Figure 1. The Île-de-France region has the highest number of cases (2,176, or 61%), followed by Occitanie (293 cases), Auvergne-Rhône-Alpes (235 cases), and Provence-Alpes-Côte d’Azur (222 cases); 20 cases are residents abroad.

For 1,042 confirmed cases (29.4%), the region of residence was unknown and was replaced by the region of reporting. The vast majority of confirmed adult cases recorded to date are male, with the exception of 56 (1.6%) female cases. Nine children under the age of 15 have been reported. Adult cases have a median age of 36 years; 25% of adult cases are under 30 years of age, and 25% are between 43 and 77 years of age.

Among the cases for which information is available, 68 (3%) were hospitalized due to their Monkeypox virus infection; this proportion has remained stable over time.

No deaths have been reported to date.

---

Focus on female cases (as of August 22, 2022)

The main characteristics of 39 confirmed female cases are as follows: their median age is 27 years (ranging from 18 to 61 years). The majority reside in the Île-de-France region. The circumstances of these women’s exposure are difficult to determine. Among the 22 women for whom information is available, 5 reported having been in contact with a person infected with monkeypox within the 3 weeks preceding the onset of symptoms. This contact occurred in the household or living environment (living with a family member or spouse). Two women reported occupations that could have exposed them to the virus (healthcare worker and hospitality industry). For the others, interview data did not allow for the identification of a presumed mode of transmission.

---

The distribution of confirmed cases by date of symptom onset (when known) is shown in Figure 2. The date of symptom onset for these cases ranges from May 7 to August 24, 2022. Due to reporting delays, data from the most recent weeks have not been consolidated.

The reports received do not always mention the date of symptom onset. As an alternative to this information, the distribution of cases by date of reporting is shown in Figure 3.

These data suggest that the peak in infections occurred in late June/early July and that the number of confirmed cases has been trending downward since then. However, we must remain very cautious, as the summer period may have led to delays in diagnosis and reporting. Similarly, some people may not have sought medical care. Several other countries, particularly in Europe, have also observed a slowdown or even a decrease in the number of new confirmed cases reported in recent weeks. This trend will need to be confirmed in the coming weeks.

Figure 1. Biologically confirmed cases of monkeypox (n=3,527 cases) by region of residence (or by region of reporting when the region of residence is unknown), France, May–August 2022 (data as of August 29, 2022 – 12:00 p.m.)

Figure 1. Cas confirmés biologiquement de variole du singe (n=3 527 cas) par région de résidence (ou par région de signalement lorsque la région de résidence est inconnue), France, mai-août 2022 (données au 29/08/2022 – 12h00)

Figure 2. Biologically confirmed cases of monkeypox (n = 2,510 cases) by week of symptom onset, France, May–August 2022 (data as of August 29, 2022 – 12:00 p.m.).

Figure 2. Cas confirmés biologiquement de variole du singe (n= 2 510 cas) par semaine de début des symptômes, France, mai-août 2022 (données au 29/08/2022 – 12h00).
The data for the past few weeks (in light blue) is not yet fully finalized.

Figure 3. Biologically confirmed cases of monkeypox (n = 3,546 cases) by week of reporting, France, May–August 2022 (data as of August 29, 2022 – 12:00 p.m.).

Figure 3. Cas confirmés biologiquement de variole du singe (n= 3 546 cas) par semaine de signalement, France, mai-août 2022 (données au 29/08/2022 – 12h00).
The data for the past week (in light blue) are not fully consolidated (the dip in reported cases observed in week 28 (July 11–17) can be attributed to the July 14 holiday).

Information and Prevention Initiatives

Given what has been observed in Europe regarding the disease, targeted communication was quickly implemented for MSM. The website sexosafe.fr, dedicated to the sexual health of MSM, is regularly updated with a summary of current knowledge on the subject and prevention measures. Poster, radio, and digital campaigns provide information to the public, complementing on-the-ground initiatives. Since June 17, the digital campaign has generated nearly 780,147 clicks on banners and over 700,578 visits to the Sexosafe website.

All information on vaccination is updated weekly on the pages for the general public and for healthcare professionals (accessible without a login) on the Vaccination-info-service website.

Prevention efforts are continuously adapted to the evolving situation and the current state of knowledge.

To make information more accessible to vulnerable people in precarious situations, a visual resource—translated into 6 languages and developed with professionals working with these individuals—is available on Sante Publique France.

The MOBCO Newsletter No. 7, developed in collaboration with frontline workers, compiles a series of questions and answers on the topic of monkeypox. It is intended for professionals and volunteers working with people in precarious situations.

In France, ongoing surveillance of monkeypox through the mandatory reporting system has been strengthened, and information and alert messages are being sent to healthcare professionals. Discussions are also continuing with other European countries, the WHO, and the ECDC.

Monkeypox Info Service: A helpline to answer questions about monkeypox

The “Monkeypox Info Service” hotline is available daily from 8 a.m. to 11 p.m. at the toll-free number 0 801 90 80 69 (free calls and services; anonymous and confidential). This service is responsible for supporting prevention messages and protective measures, providing information on symptoms, treatments, and vaccination, and offering advice and referrals to care services.

Since the hotline opened in mid-July, 6,867 calls have been handled by the Monkeypox Info Service.

  • 467 calls were handled in week 34 (compared to 547 in week 33).

  • A steady decline in the number of daily calls has been observed since Wednesday, August 10, 2022.

  • People aged 25–39 account for 47% of callers (compared to 39% in week 33).

  • The Île-de-France region remains the top source of calls, with a 13% increase compared to week 33 (60% vs. 47%).

  • There has been an increase in the percentage of healthcare professionals calling the hotline (3% vs. 1% in week 33).

  • 61% of calls concern preventive measures, focusing primarily on vaccination (how to access the vaccine, the interval between doses, particularly in cases of contact with an infected person, etc.).

Preventive Vaccination Against Monkeypox

In response to the spread of the Monkeypox virus, the High Authority for Health, following a request from the Directorate General of Health, recommended in its opinion dated July 7, 2022, that preventive vaccination be offered to groups most at risk of exposure to the virus.

Regarding the rollout of the vaccination, 127,032 doses of third-generation vaccine had been delivered by the Agency to the regions as of August 29, 2022. Deliveries are primarily made on a weekly basis.

Since July 11, 2022, in addition to individuals who have had high-risk contact with an infected person, individuals meeting the criteria established by the HAS may schedule an appointment to be vaccinated throughout the country:

  • Men who have sex with men and report having multiple sexual partners.

  • Transgender individuals reporting multiple sexual partners.

  • Sex workers.

  • Professionals working in venues where sexual services are provided.

Vaccination may also be considered on a case-by-case basis for healthcare professionals who care for infected individuals.

To learn more about vaccination and access to vaccination sites:

Smallpox B (Mpox)

thematic dossier

Smallpox B (Mpox), formerly known as monkeypox, is a rare viral infectious disease caused by the monkeypox virus and transmitted primarily from rodents to humans, and then from person to person,...

Safe Sex

HIV and STI prevention, testing, and sexual orientation—the Sexosafe website addresses issues related to sexuality among men.

Vaccination Information Service

What are vaccines for? How do they work? At what age should children be vaccinated? Vaccination-info-service.fr answers the most frequently asked questions about vaccination. A separate...